Julie Gralow, MD, of the University of Washington and the Seattle Cancer Care Alliance, recently attended the San Antonio Breast Cancer Symposium. Dr. Gralow is also a member of Lineagotica’s Editorial Board. In this podcast, she discusses the major points of this year’s symposium: better, more targeted treatments and managing side effects. These highlights include:
Strategies in the use of hormonal therapy, or endocrine therapy, in the treatment of early-stage breast cancer and metastatic breast cancer, in particular aromatase inhibitors and PI-3 kinase inhibitors [1:32].
An update on HER2-positive metastatic breast cancer research [8:57].
Research on the use of PARP inhibitors in the treatment of triple-negative breast cancer [10:37].
Helping relieve joint and muscle pain in women taking aromatase inhibitors [12:28].
This is a prerecorded audio podcast. It can be listened to online or downloaded (mp3) to your computer. A transcript of this podcast is also available. For more information, visit the Lineagotica podcast page.